11/21
09:50 am
rare
Rating for RARE
Low
Report
Rating for RARE
11/12
11:08 am
rare
Rating for RARE
Low
Report
Rating for RARE
11/6
12:54 pm
rare
Rating for RARE
Low
Report
Rating for RARE
11/6
12:23 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
11/6
12:23 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
11/6
11:59 am
rare
Rating for RARE
Low
Report
Rating for RARE
11/6
11:59 am
rare
Rating for RARE
Low
Report
Rating for RARE
11/6
09:30 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
11/6
09:26 am
rare
Rating for RARE
Medium
Report
Rating for RARE
10/22
11:39 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
10/22
11:17 am
rare
Rating for RARE
Low
Report
Rating for RARE
10/1
09:12 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
10/1
08:45 am
rare
Rating for RARE
Low
Report
Rating for RARE
9/26
10:15 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
9/26
10:15 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
9/26
10:11 am
rare
Rating for RARE
Low
Report
Rating for RARE
9/26
10:11 am
rare
Rating for RARE
Low
Report
Rating for RARE
9/20
12:26 pm
rare
Rating for RARE
Low
Report
Rating for RARE
9/16
01:06 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
9/16
12:56 pm
rare
Rating for RARE
Low
Report
Rating for RARE